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Abstract 
 
Background and Objectives: In the Control of Blood Pressure and Risk Attenuation 
(COBRA) trial, a 2×2 factorial design study (2004-2007), the combined home health 
education (HHE) and trained general practitioner (GP) intervention delivered over 2 
years was more effective than no intervention (usual care) in lowering systolic blood 
pressure (BP) among adults with hypertension in urban Pakistan. We aimed to assess the 
effectiveness of the interventions on kidney function. 
 
Design, Participants, Settings, and Methods: During 2012-2013, we conducted 
extended follow-up of a total of 1271 individuals 40 years or older with hypertension 
(systolic BP >140 mm Hg or diastolic BP ≥90 mm Hg, or already receiving treatment) 
and serum creatinine measurements with 2 years in-trial and 5 years of post-trial period in 
12 randomly selected low income communities in Karachi, Pakistan. The change in 
estimated glomerular filtration rate (eGFR) from baseline to 7-year was assessed among 
randomized groups using generalized estimating equation methodology with multiple 
imputation of missing values.  
 
Findings: At 7 years of follow up, adjusted mean eGFR levels remained unchanged at -
0.3 (95% CI) (-3.5, 2.9) ml/min/1.73m2 among adults randomised to the combined HHE 
plus trained GP intervention compared to a significant decline of -3.6 (-5.7, -2.0) 
ml/min/1.73m2 in those randomised to Usual Care (p =0.008, modified intention-to-treat 
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(ITT) analysis). The risk for the combined intervention of death from kidney failure or 
>20% decline in eGFR relative to usual care was significantly reduced (RR= 0.47; 95% 
CI: 0.25, 0.89).  
Conclusions: The combined HHE plus trained GP intervention is beneficial in preserving 
kidney function among adults with hypertension in communities in Karachi. These 
findings highlight the importance of scaling-up simple strategies for renal risk reduction 
in low- and middle- income countries.  
Primary Funding Source: Wellcome Trust. 
(ClinicalTrials.gov registration number: NCT00327574) 
 
(Words 291)  
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Introduction 
Chronic kidney disease (CKD) is ranked as the 18th leading (and rising) cause of 
mortality by the Global Burden of Disease Study 2010. (1) About 1 in 5 adults suffers 
from CKD in South Asia. (2) (3) However, evidence to inform prevention strategies for  
CKD is scarce, especially in low- and middle- income countries (LMICs).  
 
Glomerular filtration rate (GFR) is an excellent marker of kidney function. Decline in 
GFR is a strong predictor of progression to advanced stages of CKD, and thus a valid 
subclinical marker in observational studies and clinical trials. (4, 5) 
 
We previously reported 2-year outcomes of the Control of Blood Pressure and Risk 
Attenuation-(COBRA) trial (2004 to 2007) in Karachi, Pakistan. (6) The main trial was 
designed to assess the impact of family-based home health education (HHE) delivered 
every three months to households in randomized clusters, and a second approach of 
training general practitioners (GP) to manage hypertension optimally. We found that the 
combined strategy (HHE plus trained GP) was the most beneficial for lowering blood 
pressure (BP) in people with hypertension at 2 years, with a reduction of 5 mm Hg in 
systolic BP compared to no intervention (usual care). (6) The benefit of intervention on 
BP was attenuated to 2.1 mm Hg but still evident at 7 years. (7)However, it remains 
unclear whether the benefit translates into preservation of kidney function among 
individuals with hypertension. Clearly, a broader scope of benefit and associated 
advantages in cost-effectiveness would increase the likelihood of wider adoption of these 
interventions in public health programs.  
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We therefore conducted a 7-year follow-up of all the COBRA trial participants, 
inclusive of the 2-year in-trial and 5-year post-intervention period, to determine the 
impact of trial interventions on change in estimated glomerular filtration rate (eGFR) 
among adults with hypertension in Karachi, Pakistan. We also tracked all-cause mortality 
and death from kidney failure among the trial participants.  
 
We hypothesized that adults with hypertension randomized to the HHE plus trained GP 
intervention would exhibit a slower decline in eGFR than those randomised to a single 
intervention (GP only, HHE only) or no intervention.  
Methods  
Ethical approval for the main trial and the post intervention follow-up were obtained 
from the Ethics Review Committee at the Aga Khan University. Informed consent was 
obtained from all participants. 
COBRA Trial Description 
As previously described, the COBRA trial was a 2×2 factorial design cluster randomized 
controlled trial to determine the impact of family based HHE and/or special training of 
GPs on the BP levels of adults with hypertension (registration number 
NCT00327574, ClinicalTrials.gov).  (6)  Briefly, 12 communities (with about 250 
households each) were randomly selected using multi-stage sampling from middle to low 
income areas in Karachi. Eligibility criteria for study enrolment were individuals residing 
in the selected clusters and aged 40 years or older with known hypertension, or with 
consistently elevated BP on two separate visits (mean of last two of three measurements 
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of systolic pressure ≥140 mm Hg or mean diastolic pressure ≥90 mm Hg). Computer 
generated codes were used to randomly assign the 12 clusters to four groups of 3 clusters 
each: HHE only, trained GP only, HHE plus trained GP, and no intervention (usual care). 
A total of 1341 adults from the 12 randomly selected clusters were included in the 
trial. (6) 
Home Health Education (HHE): trained community health workers (CHWs) visited 
households and delivered healthy lifestyle messages.  (reduce dietary sodium, total and 
saturated fat consumption, increase fruit, vegetable and low fat dairy product intake, 
smoking cessation, maintain a normal body weight, and increase physical activity) using 
a behaviour change communication strategy.  In addition, they underscored the 
importance of adherence to antihypertensive medications.  Home visits were made every 
three months for 2 years (i.e., the duration of the trial).  
 
General Practitioner Education: In the six study areas assigned to this intervention, all 
GPs were invited for training. The training curriculum was based on the seventh report of 
the Joint National Committee (JNC-7) and the Fourth Working Party of the British 
Hypertension Society guidelines (8, 9) Target BP was <140/90 mm Hg for all 
individuals.  
 
Screening and Recruitment: Trained research staff visited all households in each of the 12 
clusters, and screened from all eligible adults aged 40 years or older for hypertension 
after obtaining informed consent. Those with an elevated BP or known hypertension were 
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invited to participate, and advised to consult a local GP. The baseline measurements were 
conducted over one year during 2004 – 2005. 
 
A routine physical examination was performed and a fasting blood specimen collected in 
the morning after an overnight fast. First morning urine sample was collected and 
concentrations of albumin and creatinine were measured.  
 
Serum creatinine measurements were calibrated at the Cleveland Clinic laboratory-
reference laboratory, where serum creatinine levels were measured again using the Roche 
enzymatic creatinine assay (in duplicate) which is traceable to the National Institute of 
Standards and Technology creatinine reference measurement. (10) Estimated glomerular 
filtration rate (eGFR) was computed using the CKD-EPI equation validated for the 
Pakistani population. (10) 
 
In-Trial Follow-up during 2 years of Intervention: Hypertensive adults were evaluated by 
trained field staff in all 4 groups, masked to randomization status, at 4-monthly intervals 
over the 2 years of intervention during which three consecutive BP readings, were taken. 
Blood and urine measurements were not collected at 2 years. 
 
Post Intervention Follow-up 
 
Trained outcomes assessors masked to randomization status visited the homes of the 
participants seven years post randomization (2012-2013) to establish contact and track 
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vital status. Informed consent was obtained for participation in the study.  
 
BP was measured. Fasting blood and urine samples were collected using the same 
protocol as during baseline.  
 
Mortality tracking: For individuals who had reportedly died, a dedicated field team 
contacted the next of kin or nearest relative to verify mortality  Efforts were made to 
obtain information on the cause and date of death, and death certificates were tracked 
from the hospital and/or the graveyard, and the district mortality registers. 
 
Analysis:  
No power calculations were done as this was a post-trial follow-up.  
 
Primary Outcome: The primary outcome for the analysis was change in CKD-EPI 
eGFR from baseline to 7-year post-trial follow-up visit.  
 
Secondary Outcomes: 1) greater than 20% decline in eGFR  from baseline to 7-year 
follow-up; 2) mortality from kidney failure;  3) composite of > 20% decline in eGFR 
from baseline to 7-year follow-up visit or all-cause mortality; 4) composite of > 20% 
decline in eGFR from baseline to 7-year follow-up visit or death from kidney failure.  
In addition, we also evaluated change in urine albumin to creatinine ratio (ACR) from 
baseline to end of 7- year follow-up.  
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Statistical Analysis: 
Analyses were performed using STATA version 12 and SAS version 9.13. Extreme 
outliers (change in eGFR ±31 ml/min/1.73m2 during 7 years defined as 3 times IQR of 
change in eGFR) corresponding to 90th or 10th percentile cluster specific values were 
truncated. (11)  
Main analyses were performed on all participants with baseline eGFR measurements 
under a modified intention-to-treat (ITT) principle —modified ITT because not all 
randomized patients (n=1341) were entered into the final analysis as those without 
baseline eGFR were excluded (n=70) from all analyses.  
The multiple regression was adjusted for clustering, and known predictors of CKD 
including age at baseline, sex, baseline systolic and diastolic BP, BMI, baseline eGFR, 
baseline ACR, and presence of diabetes. (12) (13) (14) At the 2-year post-intervention 
follow-up analysis which employed a conventional main effect and interaction model for 
a 2×2 factorial design, a statistically significant interaction between the HHE and the 
trained GP study intervention factors was detected and reported. Consequently, at the 7-
year follow-up, the standard factorial analysis was abandoned in favour of a more 
interpretable one-way layout approach comparing treatment means among the 4 groups. 
This was the same approach used previously for the 2-year analysis. (15) (6) For 
consistency and comparability among reported results, we have employed the 4-group 
one-way layout approach in the present analysis.   
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The generalized estimating equations (GEE) approach was used in the main analysis of 
eGFR and secondary endpoints with adjustment for clustering. Multiple imputation was 
employed to handle bias due to missing 7-year eGFR (50.4%) follow-up values. All F-
tests comparing eGFR among intervention groups were GEE based and constructed from 
multiple imputation samples, with the exception of the per-protocol sensitivity analysis 
on those with eGFR available at 7 years (n=630) .      
 
Variables were included in the eGFR multiple imputation model if they were risk factors 
for progression of kidney disease. Therefore, the multiple imputation model included 
baseline age, gender, baseline BMI, history of diabetes, systolic and diastolic BP at 
baseline, eGFR at baseline, and urine albumin excretion at baseline. The resultant dataset 
allowed us to use data from all 1271 individuals randomized. Ten imputed datasets were 
generated using the fully conditional specification (FCS) method and predictive mean 
matching of continuous variables under the missing at random assumption. After 
imputation, each dataset was analysed separately the using the GEE method with F-tests 
constructed from the pooled imputed samples.   
We considered p ≤ 0.05 to be statistically significant for the omnibus tests and 
comparisons among group means; p ≤ 0.10 was considered significant for interactions. 
We report marginal adjusted means and 95% CIs for treatment effects adjusted for the 
other variables in the model. 
Logistic regression used to obtain 7 year follow-up risk ratios (RRs) and 95% 
confidence intervals (CIs) for the intervention groups relative to usual care as the 
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reference group.(16)  Miettinen’s doubling-of-cases approach was used to estimate RRs 
employing a linear mixed model for a cluster sample design with logit link, binary error 
distribution, maximum likelihood (ML) parameter estimation and sandwich method 
(robust) variance-covariance estimation. Calculations were performed using SAS PROC 
GLIMMIX with the EMPIRICAL variance estimation option. (17) 
To evaluate factors influenced by intervention that could potentially mediate the primary 
outcome, we accounted for change in systolic BP from baseline at 7-year follow up in the 
main analysis on change in eGFR. (7) 
 
 
Results: 
The consort diagram is shown in Figure 1, and baseline characteristics of clusters and 
participants are presented in Table 1. Baseline characteristics of participants alive at the 
post-trial visit are summarized in Appendix Table 1. 
 
 Response Rate during Post Trial Follow-up: At the 7-year follow up, 283 (22.3%) 
members of the original cohort with a baseline eGFR measurement had reportedly died. 
An eGFR measurement was available on 630 (64%) of the total remaining cohort with 
baseline eGFR targeted for recruitment at follow up (n=988).  Urine ACR was available 
on 648 participants at follow-up. However, comparison of characteristics between 
participants alive at the post-trial follow up with an eGFR (n=630) measurement versus 
those without an eGFR measurement (n=358) revealed no significant differences in 
baseline characteristics. (Appendix Table 1).  
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Change in eGFR: By the end of the 7-year follow-up period, mean follow-up eGFR, 
89.3 ml/min/1.73m2, was higher in the combined intervention group than in the single 
(86.8 and 82.7 ml/min/1.73m2) and no intervention (usual care) (84.9 ml/min/1.73m2) 
groups (p=0.002) (Table 2). The unadjusted change from baseline eGFR showed non-
significant increase in the combined HHE plus GP group compared to a decline in 
individuals assigned to single or no intervention (usual care) (p=0.01). (Table 2) Model-
based, adjusted mean changes in eGFR differed statistically among the 4 intervention 
groups (p =0.008). Of particular interest is that eGFR showed a non-significant change of 
-0.3 (95% CI) (-3.5, 2.9) ml/min/1.73m2 in the HHE plus GP group compared to the 
significant decline of -3.6 (-5.7, -2.0) ml/min/1.73m2 in the no intervention group 
(p=0.008 difference among groups and p=0.04 difference between groups) (Table 2). As 
shown in Figure 2, the histogram of the model-based, individual predicted changes in 
eGFR for individuals receiving the combined HHE plus trained GP intervention 
demonstrated a positive shift, indicating an increase in eGFR as compared to reductions 
in eGFR for the usual care and single intervention groups. The model residual diagnostics 
are shown in Appendix figures 1 and 2.  The intra-class coefficient for change in eGFR 
was 0.03.  
 
No significant interactions were detected between intervention and baseline 
characteristics including age, baseline systolic BP, baseline eGFR, or urine albumin 
excretion (interaction p >0.15  for each).  
In addition to the baseline variables, upon accounting for change in systolic BP from 
 14 
baseline to 7 year, the significant difference in change in eGFR among randomized group 
persisted (p=0.015), however, the level of significance between the HHE plus trained GP 
group versus usual care was attenuated. (p=0.07) (Appendix Table 2). (7) 
 
Greater Than 20% Decline In Baseline eGFR: 
Table 3 shows that the percentage of individuals with greater than 20% decline in 
baseline eGFR was lower for combined intervention (5.6%) than usual care (10.3%) 
(p=0.06).  The adjusted risk ratio (95% CI) for >20% decline in baseline eGFR for 
combined intervention relative to usual care was 0.53 (0.29, 0.96) (Table 4).  
 
All-Cause Mortality and Death from Kidney Failure: A total of 283 of 1271 (22.3%) 
participants died during the 7 years of follow up. The differences in all-cause mortality or 
death from kidney failure were not statistically significant. However, the adjusted risk 
ratio (95% CI) for the composite outcome of death from kidney failure or >20% decline 
in baseline eGFR was significantly reduced to 0.47 (0.25, 0.89) for combined 
intervention versus usual care.  (Table 4).  
 
 
Sensitivity and Subgroup analysis: The per-protocol analysis yielded results consistent 
in direction of change in eGFR among the randomized groups with eGFR showed a non-
significant increase of 1.3 (95% CI) (-2.0, 4.6) ml/min/1.73m2 in the HHE plus trained 
GP group compared to the significant decline of -4.1 (-4.8, -3.4) ml/min/1.73m2 in the no 
intervention group (p=0.3 difference among groups and p=0.002 difference between 
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groups) (Appendix Table 3).  
The analysis restricted to individuals with available information at follow-up showed 
improved adherence to antihypertensive therapy with blockers of renin angiotensin 
system in the combined HHE plus GP group (26.1%) relative to usual care (18.2%), 
albeit not statistically significant (p=0.31). (Appendix Table 4).  
 
Change in urine albumin to creatinine ratio (ACR): In the per-protocol analysis, , 
mean urine ACR (mg/g) increased in all 4 groups, with non-significant differences 
among groups (p=0.6). Adjusted mean increase (95% CI) was lowest for combined HHE 
plus trained GP intervention  at 10.3 (8.8, 11.8) mg/g, followed by HHE only  at 10.2 
(8.1, 16.2) mg/g, HHE only at 25.8 (9.1, 42.5) mg/g and usual care   at 13.4 (5.4, 21.5) 
mg/g.  
 
 
Discussion:  
After 7 years of follow up—5 years after cessation of intervention— adjusted mean eGFR 
levels remained unchanged at -0.3 (95% CI) (-3.5, 2.9) ml/min/1.73m2 among adults 
randomised to the combined HHE plus trained GP intervention compared to a significant 
decline of -3.6 (-5.7, -2.0) ml/min/1.73m2 in those randomised to usual care (p <0.008, 
modified intention-to- treat (ITT) analysis). Risks of a >20% decline in eGFR from 
baseline associated with combined intervention versus usual care was halved (RR=0.53,  
(95% CI) (0.29, 0.96)). The benefit of combined HHE plus trained GP intervention on 
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preserving kidney function highlights the potential for scaling up simple strategies to 
reduce renal risk.  
 
The combined impact of healthy lifestyle and medication could account for our findings 
of a greater impact of our combined (HHE plus trained GP) intervention versus either of 
these alone compared to usual care.  Results from trials on weight management and 
healthy diets (rich in fruit and vegetables and low in animal protein) demonstrate an 
increase in or preservation of eGFR. (18) (19) Physical activity has a beneficial impact on 
cardiometabolic parameters and observational data suggest benefit may extend to slowing 
progression of kidney disease. (20) (21) In the Look AHEAD trial, behavioural 
intervention of intensive weight loss and physical activity reduced the incidence of very 
high risk CKD (eGFR less than 45 ml/min/1.73m2) among adults with type 2 diabetes. 
(22) In terms of medication, trials of anti-hypertensive therapy, especially blockers of the 
renin-angiotensin system (RAS), demonstrate a beneficial long term effect on reduction 
in progression to kidney failure—especially among individuals with CKD. (23) (24)  
 
There are differences in population and health system characteristics between developing 
and developed countries. In Pakistan, as in many low and middle income countries, diets 
are poor in fruit and vegetables (99% have less than one serving per day), and the vast 
majority of individuals with hypertension have uncontrolled BP. (25) Thus, the scope for 
improvement from interventions targeting individual and provider behaviour is 
considerable. COBRA was designed to emphasise behaviour change of the participants 
and the providers. We demonstrated benefit of combined intervention on BP at 2 years 
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which attenuated but persisted till 7 years. The latter could only partially account for the 
observed benefit of combined intervention on eGFR. There were indications of 
improvement in behaviour (physical activity, tobacco use, adherence to antihypertensive 
medications) at 2 years. (6)  There was no intended cross over during the post trial 
follow-up, and the study clusters were geographically far apart (minimum distance 10 
kilometers). Hence it is unlikely that participants allocated to usual care would seek care 
from providers in the HHE and GP intervention areas. Furthermore, HHE intervention by 
CHWs was discontinued at 2 years. Thus, it is possible that part of the benefit of the 
combined intervention is derived from a legacy effect of improvement in diet, physical 
activity, and BP observed at 2 years, possibly acting synergistically to preserve kidney 
function in the long term.  (26) 
 
The clinical and public health implications of a greater preservation of eGFR by 3.3 
ml/min/1.73m2 over 7 years in communities randomized to the combined intervention 
compared to usual care can be substantial. In the population based Coronary Artery Risk 
Development in Young Adults (CARDIA) Study, Blacks had a 0.10 (95% [CI], −0.09 to 
0.30) ml/min/1.73m2 per year faster decline in eGFR during 10-15 years of follow-up 
compared with Whites, and were also more likely to develop CKD.  Data from 
population based studies including a meta-analysis of individual patient data on 1.7 
million participants from 35 cohorts including Asian populations provide robust evidence 
that even small decline in eGFR (e.g. 20% from baseline over 2 years) increases the 
hazard ratio (95% CI) of end stage renal disease by 2.5 (2.1 to 3.1) compared to no 
change in eGFR. (4, 5). The population attributable risk of the relatively small decrease 
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in eGFR at a population level is not trivial especially in Asian countries with a rising 
prevalence of hypertension and diabetes. (27). 
 
Our findings have limitations. First, the high mortality rate (22.3%) introduces the 
potential of healthy survivor bias in the analysis on change in eGFR. In addition, 34% of 
the trial population alive at follow-up did not have an eGFR measurement at follow-up. 
However, we used multiple imputation for missing values in the main analysis, and GEE 
which relies on population average of all available readings. Second, our study was 
under-powered to detect a difference in the hard outcome of kidney failure or other 
established endpoints of kidney disease progression including doubling of serum 
creatinine or 57% reduction in eGFR or 30% reduction in eGFR over 2 years. (5) 
Evaluation of such questions requires a much larger sample. However, lesser declines 
have been shown to correlate well with established endpoints. (28) (29) Third, as eGFR 
was not measured at the end of intervention at 2 years, it was not possible to determine 
the immediate impacts of intervention on eGFR, and therefore cannot determine whether 
continued intervention would have had a greater effect at 7 years than that which we 
showed 5 years after cessation of intervention. Fourth, the eGFR equations have not been 
validated for serial measurement in kidney function among the general population 
cohorts, and could potentially be influenced by changes in weight and muscle mass 
actively promoted by healthy lifestyle component (diet and physical activity) of the 
intervention. However, an increase in muscle mass is unlikely to bias the results in favor 
of intervention.  Finally, the study was not designed to assess the influence of individual 
components of the packaged intervention on the outcome. However, we were able 
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demonstrate the overall effectiveness of HHE combined with trained GP intervention in 
preserving kidney function in a native urban South Asian population.  
 
These findings have implications for other LMICs such as China and Latin America 
which have a similar risk factor profile, burden of hypertension and diabetes, and where 
health systems infrastructure has neglected non-communicable diseases. (30) (31)  
 
The main strengths of our study are our (i) long term follow-up information on eGFR in a 
public health intervention trial of lifestyle plus GP training on drug intervention. (32) (33) 
Our study provides an unique opportunity to examine the long term effects at 7 years in a 
representative cohort of hypertensive adults in a low-to-middle income country (LMIC) 
setting, (ii) using standardized measures of CKD-EPI with an equation validated in the 
local population,  (iii) and analysis according to the original group assignment at 
randomization. (34)  
 
In conclusion, our findings indicate that public health interventions using effective 
lifestyle modification approaches and training of providers in a primary care setting can 
yield long-term benefits for preserving kidney function. These simple strategies are 
implementable and should be evaluated for cost effectiveness of prevention of CKD in 
LMICs.  
 
(Words 3494) 
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Figure 1 Legend: *Participants with eGFR available at baseline were included in the 
modified intention to treat analysis (n=1271). Participants with eGFR at baseline and 
follow-up were included in the per-protocol analysis (n=630). 
  
 27 
Legend Figure 2: Histogram of the model-based, individual predicted changes in eGFR 
for individuals (n=1271) receiving the combined HHE plus trained GP intervention; 
single HHE only; single GP only; or usual care.  
 
 
  
 
